Investor Presentaiton
BMS-986288: A next generation CTLA-4 antibody
Overview
CTLA-4: established MOA, with Yervoy approved across
solid tumors
• Challenges (toxicity and patient selection) associated with
targeting CTLA-4 have limited development
BMS-986288 is a next-generation CTLA-4 designed to
improve the benefit/risk:
-
NF (enhanced CD16 binding) biology increases
immune priming via Fc engagement enhancing anti-
tumor response
Improves safety profile with ProbodyⓇ added to NF
allowing for combinations and moving to earlier lines
of therapy
Development plan
PoC trials in NSCLC & MSS CRC ongoing; data anticipated in
2024
MOA: A masked non-fucosylated anti-CTLA-4 antibody which
improves immune priming and the safety profile
APC
T cell
Enhanced
binding
BMS-986288
CTLA-4
CD16
CD80/86
MHC
Tumor specific antigen
CD80/86
Increased
Interaction
TCR.
CD28.
Broad range of development opportunities
Ill Bristol Myers Squibb™
Not for Product Promotional Use
152View entire presentation